HER2 Targeted Therapies: Recent Advances

Helen K. Chew, MD Professor of Medicine Division of Hematology/Oncology



Today's Talk

Advance stage

- Early stage
- Future directions



HER2-positive MBC

Setting	Regimen	Trial
1 st -line	Taxane + trastuzumab and pertuzumab	CLEOPATRA
2nd-line	Trastuzumab deruxtecan	DESTINY 03
3 rd -line	Tucatinib, trastuzumab + capecitabine	HER2CLIMB
	Trastuzumab emtansine	EMILIA
4 th line and beyond	Trastuzumab + chemotherapy	
	Lapatinib + capecitabine	
	Trastuzumab + lapatinib	
	Neratinib + capecitabine	NALA
	Margetuximab + chemotherapy	SOPHIA







DECEMBER 5-9, 2023 | @SABCSSanAntonio

HER2CLIMB-02: Primary Analysis of a Randomized, Double-blind Phase 3 Trial of Tucatinib and Trastuzumab Emtansine for Previously Treated HER2-positive Metastatic Breast Cancer


Sara A. Hurvitz, MD

Fred Hutchinson Cancer Center, Seattle, WA, USA

Sherene Loi, Joyce O'Shaughnessy, Alicia F. C. Okines, Sara M. Tolaney, Joohyuk Sohn, Cristina Saura, Xiaofu Zhu, David Cameron, Thomas Bachelot, Erika P. Hamilton, Giuseppe Curigliano, Antonio C. Wolff, Nadia Harbeck, Norikazu Masuda, Linda Vahdat, Khalil Zaman, Frances Valdes-Albini, Margaret Block, Timothy Pluard, Tira J. Tan, Chelsea D. Gawryletz, Arlene Chan, Philippe L. Bedard, Rinat Yerushalmi, Binghe Xu, Konstantinos Tryfonidis, Michael Schmitt, Diqiong Xie, Virginia F. Borges

This presentation is the intellectual property of the author/presenter. Contact them at shurvitz@fredhutch.org for permission to reprint and/or distribute

HER2CLIMB-02 Study Design



The primary analysis for PFS was planned after ≈331 PFS events to provide 90% power for hazard ratio of 0.7 at two-sided alpha level of 0.05. The first of two interim analysis for OS was planned at the time of the primary PFS analysis, if the PFS result was significantly positive.^b

NCT03975647. https://www.clinicaltrials.gov/study/NCT03975647. Accessed Oct 5, 2023.

a Patients who received prior tucatinib, atatinib, T-DXd, or any investigational anti-HER2, anti-EGFR, or HER2 TKIs were not eligible. Patients who received lapatinib and neratinib were not eligible if the drugs were received within 12 months of starting study treatment, and patients who received pyrotinib for recurrent or metastatic breast cancer were not eligible. These patients were eligible if the drugs were given for <21 days and were discontinued for reasons other than disease progression or severe toxicity. b Subsequent OS analyses are planned upon 80% and 100% of required events for the final OS analysis.

1L, first-line; BID, twice daily; cORR, confirmed objective response rate; ECOG PS, Eastern Cooperative Oncology Group performance status; IV, intravenously; LA/MBC, locally advanced or metastatic breast cancer; OS, overall survival; PFS, progression-free survival; PO, orally; R, randomization; RECIST, Response Evaluation Criteria in Solid Tumors; T-DM1, trastuzumab emtansine; T-DXd, trastuzumab deruxtecan; TKIs, tyrosine kinase inhibitors. Date of data cutoff: Jun 29, 2023. Patients were enrolled from Oct 8, 2019, to Jun 16, 2022.

Demographics and Baseline Characteristics

	T DM4 Transford	
	T-DM1 + Tucatinib	T-DM1 + Placebo
	(N=228)	(N=235)
Median age, years	55.0 (26-83)	53.0 (27-82)
(range)		
Female sex, n (%)	226 (99.1)	235 (100)
Geographic		
region, n (%)		
North America	105 (46.1)	93 (39.6)
Europe/Israel	53 (23.2)	77 (32.8)
Asia-Pacific	70 (30.7)	65 (27.7)
Hormone-receptor		
status, n (%)		
Positive	137 (60.1)	140 (59.6)
Negative	91 (39.9)	95 (40.4)
ECOG		
performance		
status score, n (%)		
0	137 (60.1)	141 (60.0)
1	91 (39.9)	94 (40.0)

	T-DM1 + Tucatinib (N=228)	T-DM1 + Placebo (N=235)
Presence or history of brain metastases, n (%)		
Yes	99 (43.4)	105 (44.7)
Active	50 (21.9)	57 (24.3)
Treated stable	49 (21.5)	48 (20.4)
No ^a	129 (56.6)	130 (55.3)
Stage at initial diagnosis, n (%) ^ь		
0-111	120 (52.6)	130 (55.3)
IV	103 (45.2)	98 (41.7)

a Includes 2 patients with missing brain metastases data.

b Five patients in T-DM1 + Tucatinib arm and 7 patients in T-DM1 + Placebo arm had unknown stage.

ECOG, Eastern Cooperative Oncology Group; T-DM1, trastuzumab emtansine.

Date of data cutoff: Jun 29, 2023.

This presentation is the intellectual property of the author/presenter. Contact them at shurvitz@fredhutch.org for permission to reprint and/or distribute


Prior Systemic Therapies

	T-DM1 + Tucatinib (N=228)	T-DM1 + Placebo (N=235)
Median prior lines of systemic therapy in metastatic setting (range)	1 (0-8)	1 (0-6)
Prior lines of systemic therapy in metastatic setting, n (%)		
0	29 (12.7)	33 (14.0)
1	146 (64.0)	150 (63.8)
2	36 (15.8)	31 (13.2)
≥3	17 (7.5)	21 (8.9)
Received prior pertuzumab treatment, n (%)	202 (88.6)	214 (91.1)
Received prior anti-HER2 TKIs, n (%)	3 (1.3)	5 (2.1)

T-DM1, trastuzumab emtansine. Date of data cutoff: Jun 29, 2023.

This presentation is the intellectual property of the author/presenter. Contact them at shurvitz@fredhutch.org for permission to reprint and/or distribute

Progression-Free Survival



HR, hazard ratio; PFS, progression-free survival; T-DM1, trastuzumab emtansine. Date of data cutoff: Jun 29, 2023.

This presentation is the intellectual property of the author/presenter. Contact them at shurvitz@fredhutch.org for permission to reprint and/or distribute

PFS in Prespecified Subgroups

Favors T-DM1 + Tucatinib


	T-DM1 + Tucatinib (N=228) Events/N	T-DM1 + Placebo (N=235) Events/N		Hazard Ratio with 95% Cl		T-DM1 + Tucatinib (N=228) Events/N	T-DM1 + Placebo (N=235) Events/N		Hazard Ratio with 95% Cl
ITT Analysis	151/228	182/235	⊨ -{	0.76 (0.61, 0.95)	Age	Lventon	LVOIND/IT		3070 01
Baseline brain metasta					<65 years	126/186	155/201	ŀ■ĺ	0.80 (0.62, 1.02)
Yes	70/99	85/105	⊢ ∎-	0.64 (0.46, 0.89)	≥65 years	25/42	27/34	⊢ ∎–-	0.61 (0.33, 1.11)
No	80/127	97/130	⊦∎H	0.88 (0.65, 1.19)	Race				
Line of treatment for m	netastatic disease				White	68/101	76/102	⊢ ∎-H	0.79 (0.55, 1.13)
First	16/26	21/28	⊢	0.51 (0.23, 1.12)	Asian	45/66	58/65	⊢∎÷	0.73 (0.49, 1.11)
Other	135/202	161/207	ŀ ∎-Ì	0.79 (0.63, 1.00)	Others	38/61	48/68	⊢ ∎∔I	0.79 (0.48, 1.28)
ECOG performance st	atus				Initial diagnos	is			
0	86/137	109/141	⊢ ∎-I	0.66 (0.49, 0.89)	0-111	81/120	100/130	H=-	0.72 (0.53, 0.99)
1	65/91	73/94	⊢ ∎-I	0.91 (0.65, 1.28)	IV	67/103	79/98	⊦≖⊣	0.77 (0.55, 1.08)
Hormone receptor stat	tus				Prior pertuzun	nab			
Positive	85/137	107/140	⊢ ∎-Ì	0.75 (0.56, 1.01)	Yes	137/203	166/214	ŀ■ĺ	0.78 (0.62, 0.99)
Negative	66/91	75/95	H	0.82 (0.58, 1.15)	No	14/25	16/21		0.74 (0.29, 1.87)
Region								; • • • • • • • • • •	
North America	68/105	69/93	⊢ ∎-́I	0.88 (0.62, 1.26)			0.1	İ _	10
Europe/Israel	36/53	57/77	┝╼┿┨	0.75 (0.46, 1.20)			Favors T-DM1 +	Tucatinib F	avors T-DM1 + Placebo
Asia-Pacific	47/70	56/65	⊢ ∎-	0.74 (0.49, 1.12)					
		0.01		0 100	ECOG, Easter trastuzumab e		Dncology Group; ITT	, intention-to-tre	eat; PFS, progression-free survival

Date of data cutoff: Jun 29, 2023.

This presentation is the intellectual property of the author/presenter. Contact them at shurvitz@fredhutch.org for permission to reprint and/or distribute

Favors T-DM1 + Placebo

PFS in Patients with Brain Metastases




a The outcome was not formally tested.

HR, hazard ratio; PFS, progression-free survival; T-DM1, trastuzumab emtansine.

Date of data cutoff: Jun 29, 2023.

Overall Survival



a The proportional hazard assumption was not maintained post-18 months, with extensive censoring on both arms.

HR, hazard ratio; NR, not reached; OS, overall survival; T-DM1, trastuzumab emtansine.

Date of data cutoff: Jun 29, 2023.

This presentation is the intellectual property of the author/presenter. Contact them at shurvitz@fredhutch.org for permission to reprint and/or distribute

Overall Safety Summary

	T-DM1 + Tucatinib (N=231) n (%)	T-DM1 + Placebo (N=233) n (%)
Any TEAE	230 (99.6)	233 (100)
Grade ≥3 TEAE	159 (68.8)	96 (41.2)
Any TESAE	70 (30.3)	52 (22.3)
TEAE leading to death	3 (1.3)	2 (0.9)
Discontinued tucatinib or placebo due to TEAE	40 (17.3)	16 (6.9)
Discontinued T-DM1 due to TEAE	47 (20.3)	26 (11.2)

Median duration of tucatinib or placebo treatment: 7.4 months for T-DM1 + Tucatinib and 6.2 months for T-DM1 + Placebo Median duration of T-DM1 treatment: 7.5 months for T-DM1 + Tucatinib and 6.2 months for T-DM1 + Placebo

Most common TEAEs (≥2%) leading to tucatinib or placebo discontinuation (T-DM1 + Tucatinib vs T-DM1 + Placebo):

• ALT increased (2.6% vs 0%)


Most common TEAEs (≥2%) leading to T-DM1 discontinuation (T-DM1 + Tucatinib vs T-DM1 + Placebo):

- ALT increased (2.2% vs 0%)
- Thrombocytopenia (2.2% vs 0%)
- Interstitial lung disease (0% vs 2.1%)

ALT, alanine aminotransferase; T-DM1, trastuzumab emtansine; TEAE, treatment-emergent adverse event; TESAE, treatment-emergent serious adverse event. Date of data cutoff: Jun 29, 2023.

This presentation is the intellectual property of the author/presenter. Contact them at shurvitz@fredhutch.org for permission to reprint and/or distribute

Most Common TEAEs (≥20%)



Most common (≥5%) grade ≥3 TEAEs (T-DM1 + Tucatinib vs T-DM1 + Placebo): ALT increased (16.5% vs 2.6%), AST increased (16.5% vs 2.6%), anemia (8.2% vs 4.7%), thrombocytopenia (7.4% vs 2.1%), and fatigue (6.1% vs 3.0%)

TEAEs occurring in ≥20% of patients in T-DM1 + Tucatinib arm are shown.

ALT, alanine aminotransferase; AST, aspartate aminotransferase; T-DM1, trastuzumab emtansine; TEAEs, treatment-emergent adverse events. Date of data cutoff: Jun 29, 2023.

HER2CLIMB-02

 Improvement in PFS (9.5 vs 7.4 months) but at increased toxicity

Tucatinib continued to improve PFS in the CNS







Trastuzumab and pertuzumab in combination with eribulin mesylate or a taxane as first-line chemotherapeutic treatment for HER2-positive, locally advanced or metastatic breast cancer: results of a multicenter, randomized, non-inferiority phase 3 trial in Japan (JBCRG-M06/EMERALD)

Toshinari Yamashita MD, PhD, Kanagawa Cancer Center, Kanagawa, Japan


Shigehira Saji, Toshimi Takano, Yoichi Naito, Michiko Tsuneizumi, Akiyo Yoshimura, Masato Takahashi, Junji Tsurutani, Tsuguo Iwatani, Masahiro Kitada, Hiroshi Tada, Natsuko Mori, Toru Higuchi, Tsutomu Iwasa, Kazuhiro Araki, Kazuko Sakai, Hiroki Hasegawa, Yohei Uchida, Satoshi Morita, Norikazu Masuda

2024 ASCO ANNUAL MEETING






Study design



- Age 20–70 years
- No prior use of chemotherapy (excluding T-DM1) for LABC/MBC
- Hormonal or anti-HER2 therapy alone, or their combination as treatment for recurrence, were allowed
- ECOG performance status score 0/1
- Left ventricular ejection fraction (LVEF) ≥50%
- Major organ function preserved
- At least 6 months since prior neoadjuvant or adjuvant cytotoxic chemotherapy

Stratification factors for randomization

- History of perioperative use of taxane
- Prior treatment with HER2-targeting antibody-drug conjugate after recurrence
- Presence of visceral metastases



^aTrastuzumab (H) : 8 mg/kg loading dose, 6 mg/kg subsequent doses + pertuzumab (P): 840 mg/body loading dose, 420 mg/body subsequent doses Treatment continued to disease progression or unmanageable toxicity

JBCRG-M06/EMERALD: A multicenter, randomized, non-inferiority phase 3 trial (UMIN000027938; ClinicalTrials.gov identifier, NCT03264547)



#ASCO24 PRESENTED BY: Toshinari Yamashita MD, PhD

Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org.



therapy

Sample size and non-inferiority testing


- Sample size was calculated for a statistical power of 80%, a significance level of 0.05 (two-sided), and an expected median PFS in the control group of 14.2 months
- Non-inferiority was tested using the Cox proportional hazards model to estimate hazard ratios (HRs) for PFS events
- The upper limit of acceptance of non-inferiority HR margins (1.33 and 1.25) was tested in a stepwise manner, and superiority was to be tested if the upper limit of the 95% CI of HR was < 1.25







PFS (primary endpoint)



#ASCO24 PRESENTED BY: Toshinari Yamashita MD, PhD


2024 ASCO

Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org.



11

PFS (primary endpoint)



#ASCO24 PRESENTED BY: Toshinari Yamashita MD, PhD


2024 ASCO

ANNUAL MEETING

Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org.



Response rate



ORR, Objective response rate; CBR, clinical benefit rate; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; NE, non-evaluable

2024 ASCO ANNUAL MEETING


#ASCO24

PRESENTED BY: Toshinari Yamashita MD, PhD Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org ASCO AMERICAN SOCIETY OF CLINICAL ONCOLOGY KNOWLEDGE CONQUERS CANCER

14

2024 ASCO


ANNUAL MEETING



#ASCO24 PRESENTED BY: Toshinari Yamashita MD, PhD Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org



Drug-related treatment-emergent adverse events Special interest



JBCRG-m06 EMERALD

 First-line eribulin was noninferior to taxane in combination with HP

• Similar (vs less toxic??) side effect profile







DECEMBER 5-9, 2023 | @SABCSSanAntonio

A phase III study comparing trastuzumab emtansine with trastuzumab, pertuzumab, and docetaxel in older patients with advanced-stage HER2-positive breast cancer. (JCOG1607 HERB TEA study)

Akihiko Shimomura, Kenji Tamura, Keita Sasaki, Ryo Sadachi, Akihiko Suto, Masataka Sawaki, Yasuaki Sagara, Naohito Yamamoto, Tomoyuki Yoshiyama, Takako Hayashi, Eriko Tokunaga, Takashi Yamanaka, Chikako Shimizu, Tadahiko Shien, Hiroji Iwata

Department of Breast and Medical Oncology, National Center for Global Health and Medicine, Tokyo, Japan, Department of Medical Oncology, Shimane University Hospital, Shimane, Japan, JCOG Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan, Department of Breast Surgery, National Cancer Center Hospital, Tokyo, Japan, Department of Breast Oncology, Aichi Cancer Center, Aichi, Japan, Department of Breast and Thyroid Surgical Oncology, Sagara Hospital, Kagoshima, Japan, Division of Breast Surgery, Chiba Cancer Center, Chiba, Japan, Department of Breast Surgery, NHO Kure Medical Center and Chugoku Cancer Center, Hiroshima, Japan, Department of Breast Surgery, NHO Nagoya Medical Center, Aichi, Japan, Department of Breast Oncology, NHO Kyushu Cancer Center, Fukuoka, Japan, Department of Breast Surgery and Oncology, Kanagawa Cancer Center, Kanagawa, Japan, Department of Breast and Endocrine Surgery, Okayama University Hospital, Okayama, Japan



This presentation is the intellectual property of the author/presenter. Contact them at Akihiko Shimomura for permission to reprint and/or distribute

Study Design


Primary endpoint:

Overall survival (OS)

Secondary endpoints:

Progression-free survival, Cumulative breast cancer specific survival, Response rate, Adverse events, Serious adverse events, Proportion of nondeteriorating of instrumental activities of daily living

• Older patients with advanced HER2positive breast cancer



N=148

- No prior chemotherapy for MBC
- Over 65 years and old
- PS 0 to 2 (0 to 1 for over 75 y.o.)

*Planned sample size: 250 Pts. Terminated early at 148 Pts by interim analysis because the OS hazard ratio estimate exceeded the non-inferiority margin (data cutoff 12/22/2022). The data cutoff for this presentation is 6/15/2023.

Arm A: HPD arm (N=75)

Trastuzumab (6 mg/kg, loading dose 8 mg/kg) + Pertuzumab (420 mg, loading dose 840 mg) + Docetaxel (60 mg/m²) q3w until PD

The dose up of Docetaxel (75 mg/m²) from the second cycle was allowed based on the data regarding safety during the first cycle.


Arm B: T-DM1 arm (N=73)

T-DM1 (3.6 mg/kg) q3w until PD

JCOG Japan Clinical Oncology Group


UMIN-CTR:UMIN000030783

Overall Survival



San Antonio Breast Cancer Symposium[®] | @SABCSSanAntonio

Progression-free Survival



San Antonio Breast Cancer Symposium[®] | @SABCSSanAntonio

Safety (adverse events reported in at least 10% of patients in either arm)

		HPD		T-DM1	
		Grade \geq 3	Grade 4	Grade \geq 3	Grade 4
Any AE		56.8%	0%	34.7%	1.4%
Hematologic	Leukopenia	26.0%	8.2%	0%	0%
	Neutropenia	30.1%	21.9%	0%	0%
	Thrombocytopenia	0%	0%	16.7%	0%
Non-	AST increased	0%	0%	15.3%	0%
Hematologic	ALT increased	2.7%	0%	16.7%	0%
	Diarrhea	12.2%	0%	0%	0%
	Fatigue	21.6%	0%	5.6%	0%
	Appetite loss	10.8%	0%	8.3%	0%





 TDM-1 failed to demonstrate noninferiority to HPD in OS and PFS in the elderly population







Primary results from PATRICIA Cohort C (SOLTI-1303), a randomized phase II study evaluating palbociclib with trastuzumab and endocrine therapy in pretreated HER2positive and PAM50 luminal advanced breast cancer.

Eva Ciruelos, Tomás Pascual, Guillermo Villacampa, Sonia Pernas, Rodrigo Sanchez Bayona, José Ponce, Blanca Cantos, Santiago Escrivá-de-Romaní, Antonia Perelló, Alvaro Montaño, Eduardo Martínez, Ana Lopez, Mireia Mele, Juan de la Haba, Javier Cortés, Mafalda Oliveira, Lorea Villanueva, Xavier Gonzalez, Patricia Villagrasa and Aleix Prat

Presenter: Eva M Ciruelos MD, PhD.

Medical Oncology Dpt

University Hospital 12 de Octubre

HM Hospitals



#ASCO24 PRESENTED BY: EVa M Ciruelos MD, PhD. Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org



Background

#ASCO24



- The incorporation of novel anti-HER2 drugs has changed the treatment landscape of HER2+ advanced breast cancer, but new treatment options are still needed.
- In advanced HR+/HER2+ breast cancer, the combination of the CDK4/6 inhibitor abemaciclib with fulvestrant and trastuzumab showed improved PFS versus standard of care chemotherapy plus trastuzumab (MonarcHER, NCT02675231)¹.
- SOLTI-1303 PATRICIA cohorts A and B (NCT02448420) evaluated palbociclib plus trastuzumab +/letrozole in postmenopausal patients with advanced HER2+ breast cancer².
 - Combination was feasible and safe.

PRESENTED BY: EVA M Ciruelos MD. PhD.

Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org

- PAM50 LumA or LumB subtypes had superior PFS compared to non-luminal subtypes: 10.6 vs 4.2 months, adjusted hazard ratio 0.40 (p 0.003).
- Cohort C of PATRICIA has prospectively enrolled patients with HR+/HER2+ and PAM50 Luminal A or B tumors to further explore the strategy of using a chemotherapy-free regimen.


¹ Tolaney S (2020). Lancet Oncol, 21(6):763-775 ² Ciruelos E. et al. (2020). Clin Cancer Res. 26(22):5820-5829





PATRICIA Cohort C: Study design

Open-label, multicenter, randomized phase II trial



(1) Including trastuzumab and/or anti-HER2 ADC for ABC ;or recurrence during or within 12 months after completing adjuvant trastuzumab and/or anti-HER2 ADCs and metastatic disease diagnosis.

(2) No evidence of progression, >3 wks between completion of local therapy study treatment initiation, and stable doses or no need of corticosteroids.

(3) Evaluated in primary or metastatic (preferred) sample.

#ASCO24

(4) Patients that are initially allocated in the TPC i) have a documented disease progression and ii) meet inclusion criteria after progression, can be re-randomized to receive the experimental or control treatment.

2024 ASCO ANNUAL MEETING PRESENTED BY: EVA M Ciruelos MD, PhD.

Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org.



Statistical considerations



Protocol assumptions


- · Sample size of 102 patients
- One-sided stratified log-rank test (0.1 alpha)
- Target PFS hazard ratio (HR): 0.62
- To achieve 80% statistical power, 80 PFS events were needed

Feb 2021: Re-randomization design

- Patients allocated in the TPC arm could be re-randomized after disease progression if the inclusion criteria were met
- Mixed effects Cox models were used to adjust for intra-patient correlation
- The re-randomization approach led to unbiased treatment estimation, correct type I error and potentially reduce number of patients to be pre-screened¹⁻². Overall survival was not assessed as a trial endpoint.
- The trial was closed earlier after 73 patients were randomized due to low recruitment. At data cut-off, 51 PFS events were observed. The study was underpowered based on the protocol assumptions (64% statistical power)



Patient's disposition






PRESENTED BY: EVA CITUEIOS MD, PhD. Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org





Primary objective: Investigator-assessed PFS



Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org

MERICAN SOCIETY O LINICAL ONCOLOGY KNOWLEDGE CONQUERS CANCER

SOLTI



Summary of AEs

AE, n (%)	Palbociclib + T + ET (N=39)*	TPC (N=32)
Any AE	36 (92.3)	28 (87.5)
Grade ≥3	24 (61.6)	16 (50.1)
Any TRAE	34 (87.2)	30 (93.8)
Grade ≥3	20 (51.3)	9 (28.1)
Dose reductions	13 (33.3) ^a	9 (28.1)
AE leading to permanent discontinuation due to toxicity	0	2 (6.3) ^b
Deaths due to adverse events	0	0

AE, adverse event; TRAE, treatment-related adverse event.

*1 patient randomized to TPC received P+T+ET

^a 76.9% of dose reductions associated with neutropenia

^b 1 patient due to recurrent grade 3 neutropenia; 1 patient due to heart failure



PRESENTED BY: EVa M Ciruelos MD, PhD. Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org.





 In advanced HR+ and HER2+ breast cancer and PAM50 luminal A or B intrinsic subtypes, the combination of trastuzumab, ET and palbociclib was feasible

 Hard to draw conclusions from small, underpowered, randomized phase II study



HER2-positive MBC

Setting	Regimen	Trial	
1 st -line	Taxane + trastuzumab and pertuzumab	CLEOPATRA	Eribulin?
2nd-line	Trastuzumab deruxtecan	DESTINY 03	
3 rd -line	Tucatinib, trastuzumab + capecitabine	HER2CLIMB	TDM-1 + tucatinib?
	Trastuzumab emtansine	EMILIA	
4 th line and beyond	Trastuzumab + chemotherapy		
	Lapatinib + capecitabine		
	Trastuzumab + lapatinib		
	Neratinib + capecitabine	NALA	
	Margetuximab + chemotherapy	SOPHIA	

Today's Talk

Advance stage

- Early stage
- Future directions







DECEMBER 5-9, 2023 | @SABCSSanAntonio

Phase III study of adjuvant ado-trastuzumab emtansine vs trastuzumab for residual invasive HER2-positive early breast cancer after neoadjuvant chemotherapy and HER2-targeted therapy: KATHERINE final IDFS and updated OS analysis

Sibylle Loibl, Max S. Mano, Michael Untch, Chiun-Sheng Huang, Eleftherios P. Mamounas, Norman Wolmark, Adam Knott, Asna Siddiqui, Thomas Boulet, Beatrice Nyawira, Eleonora Restuccia, Charles E. Geyer, Jr.

Presenting author: Prof. Dr. Sibylle Loibl, M.D., Ph.D


German Breast Group, Neu-Isenburg; Centre for Haematology and Oncology Bethanien, Goethe University, Frankfurt, Germany



IDFS, invasive disease-free survival; OS, overall survival.

KATHERINE study design

- Prior neoadjuvant therapy consisting of:
 - Minimum 6 cycles of chemotherapy
 - Minimum 9 weeks of trastuzumab
 - Second HER2-targeted agent allowed
- Residual invasive tumor in breast or axillary nodes
- Randomization within 12 weeks of surgery





 Switch to trastuzumab permitted if T-DM1 discontinued due to AEs

- Primary endpoint: IDFS
- Secondary endpoints: IDFS with second primary non-breast cancers included, DFS, OS, DRFI, safety, and QoL
- Stratification factors: Clinical stage at presentation (inoperable vs operable), HR status, preoperative HER2-directed therapy, pathologic nodal status after preoperative therapy

AE, adverse event; DFS, disease-free survival; DRFI, distant recurrence-free interval; HR, hormone receptor; IDFS, invasive disease-free survival; IV, intravenous; OS, overall survival; Q3W, every 3 weeks; QoL, quality of life; R, randomized; T-DM1, ado-trastuzumab emtansine. Adapted from *N Engl J Med*, von Minckwitz *et al.*, Trastuzumab emtansine for residual invasive HER2-positive breast cancer, Vol. 380, Pages 617–628. Copyright[©] (2019) Massachusetts Medical Society.


KATHERINE primary analysis (2018)






CCOD: July 25, 2018; median follow-up: 41.4 months (T-DM1) and 40.9 months (trastuzumab). CCOD, clinical cutoff date; CI, confidence interval; IDFS, invasive disease-free survival; OS, overall survival; T-DM1, ado-trastuzumab emtansine. Adapted from N Engl J Med, von Minckwitz et al., Trastuzumab emtansine for residual invasive HER2-positive breast cancer, Vol. 380, Pages 617–628. Copyright[©] (2019) Massachusetts Medical Society.

KATHERINE IDFS final analysis; median follow-up 8.4 years (101 months)



* p-value for IDFS is now exploratory given the statistical significance was established at the primary analysis. CI, confidence interval; IDFS, invasive disease-free survival; T-DM1, ado-trastuzumab emtansine.


Site of first occurrence of an IDFS event



* CNS metastases as component of distant recurrence (isolated or with other sites).

CNS recurrence after first IDFS event: 19 patients (2.6%) in the trastuzumab arm and four patients (0.5%) in the T-DM1 arm. CNS, central nervous system; IDFS, invasive disease-free survival; T-DM1, ado-trastuzumab emtansine.

KATHERINE 2nd OS interim analysis; median follow-up 8.4 years (101 months)



Significant reduction in risk of death by 34% with T-DM1

CI, confidence interval; OS, overall survival; T-DM1, ado-trastuzumab emtansine.



 Reassuring OS data on a regimen that has been FDAapproved since 2019.

 Although small numbers, patients who received pertuzumab and those with small volume residual disease benefitted.

 More toxicities with TDM-1 so the approach should be individualized and monitored.



Future Directions

 DB-09: THP vs T-Dxd vs T-Dxd + P in first-line HER2positive breast cancer

 PATINA: H +/-P + ET after induction chemo vs H +/-P + ET + palbociclib



Thank you!

Questions?

